445 - 456 of 7742 results
0.25 CME CREDIT

What Happened to My Furosemide? Torsemide for Congestive Heart Failure - Frankly Speaking EP 174

Guest: Jill Terrien PhD, ANP-BCMusic Credit: Richard Onorato

0.25 CME

In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.


0.25 CME CREDIT

This podcast will provide an update on the medical literature and practice guidelines pertaining to exercise. Participants will deepen their understanding of the physical and mental health benefits of exercise and will examine the evidence for a variety of common approaches to exercise (cardiovascular, strength training, high intensity interval training). Barriers to participation in exercise regimens – both for patients and providers – will be explored.


1.5 CME CREDITS

Shedding Light on Shingles: The Power of Prevention

1.50 CME
1.50 AANP | 0.36 Pharmacology

Shingles, or herpes zoster (HZ), is a common secondary infection. More than 95% of immunocompetent individuals aged > 50 years are seropositive for the varicella zoster virus and are at risk of developing shingles. This Virtual Expert Roundtable will address the pathophysiology, clinical presentation, and complications of shingles, in addition to the strategies to prevent it.


0.5 CME CREDIT

In the eleventh episode of Pri-Med’s weekly web series on COVID-19, faculty will discuss recent publications and issues related to COVID-19 including the retraction of two major trials on hydroxychloroquine from Lancet and NEJM, the results of a trial investigating hydroxychloroquine as post-exposure prophylaxis for COVID-19, and the results of a study investigating transmission and viral shedding of COVID-19. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/10/2020 and they are subject to change as new information is published.


0.5 CME CREDIT

In the twelfth episode of Pri-Med’s weekly web series on COVID-19, faculty will discuss the most recent information on COVID-19 vaccines and testing. This episode will review the mechanisms and clinical trial status of each vaccine currently in development and discuss recent literature comparing different sampling techniques in COVID-19 testing. Lastly, faculty will explore how pre-test probability is important to understanding test accuracy. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/16/2020 and they are subject to change as new information is published.


1 CME CREDIT

In the eighth episode of Pri-Med’s weekly web series on COVID-19, faculty will continue their discussion on treatment by describing immunomodulatory therapies and additional antivirals under investigation for COVID-19. They will also review the various types of vaccines currently in development for COVID-19. Specific therapies to be discussed in this episode will include: • Antivirals: baloxavir marboxil, favipiravir, nitazoxanide, oseltamivir, ribavirin, umifenovir • Glucocorticoids • Anakinra • Tocilizumab • Interferon beta-1b • Vaccine mRNA-1273 Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 05/21/2020 and they are subject to change as new information is published.


REGENERON AND SANOFI GENZYME

Learn More About the Impact and Management of Moderate-to-Severe Atopic Dermatitis in Appropriate Patients ©2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 12/2020 DER.20.08.0013


Jardiance<sup>®</sup> (empagliflozin) tablets

To learn more about JARDIANCE safety and efficacy data as well as information about initiating JARDIANCE in your patients, please access the below link.                                                                                                                                                                                    www.JARDIANCELectureSeries.com                                                                                                                                                                               Copyright © 2020 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (11/20) EM-US-101640


0.75 CME CREDIT

Join an interactive session that simulates a consult with a rheumatologist and addresses the most commonly posed questions from primary care practitioners.


0.75 CME CREDIT

Alzheimer’s disease and Parkinson’s disease are the two most common neurodegenerative disorders, affecting over 6 million people in the U.S. Like nearly all of this class of disorders, these two conditions are due to the misfolding and accumulation of proteins in the central nervous system. This new way of viewing these conditions, as protein misfolding disorders, will be presented. We will review amyloid, tau and alpha-synuclein, the proteins that build up respectively in plaques, tangles and lewy bodies. We’ll review currently available therapies and the therapies that are being developed to more directly attack these disorders and hopefully modify the course of the disease.


0.75 CME CREDIT

Primary care providers frequently encounter various types of chronic non-cancer pain in their practice, including chronic low back pain, chronic headache, fibromyalgia, neuropathic pain, osteoarthritis, and others. Best practices for the management of chronic non-cancer pain consist of a multimodal approach, with the optimal incorporation of non-opioid treatment approaches. This session will describe multiple approaches to non-opioid pain management for the primary care. Strategies include both pharmacologic and non-pharmacologic approaches as well as interventional approaches. Recognizing that some of these may require referral to a specialist, the primary care provider, with heightened awareness of multiple non-opioid pain management treatments, will be able to more comprehensively evaluate and treat their patients with chronic pain.


1 CME CREDIT

Irritable bowel syndrome (IBS) is the most common disorder seen and treated by gastroenterologists. Despite this, many physicians have difficulty making a definitive diagnosis and approximately 75% of the general population with IBS symptoms remains undiagnosed. Part of this stems from the fact that there are currently no diagnostic studies which conclusively confirm IBS. As such, it has been and continues to be considered a diagnosis of exclusion when in reality newer diagnostic criteria and minimal diagnostic testing can lead to a diagnosis with 98-99% accuracy. A better understanding of the underlying pathophysiology of this disorder has also let to more accurate treatment strategies. In this discussion we will dispel many of the myths and misconceptions surrounding this syndrome.